Evidence map›Paper›PMID 35327559›Full record

ReviewBiomolecules2022

The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.

Abdelhakim Bouyahya, Hamza Mechchate, Loubna Oumeslakht, Ikrame Zeouk, Sara Aboulaghras, Abdelaali Balahbib, Gokhan Zengin, Mohammad Amjad Kamal, Monica Gallo, Domenico Montesano and 1 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06982768 (Epigenetic Mechanisms Bridging Research and Clinical Examination in hMLH1 Hypermethylated Gastric Cancer), which is not on this map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06982768 active not recruitingnot on this mapstarted 2024, after this paper: background citation

Epigenetic Mechanisms Bridging Research and Clinical Examination in hMLH1 Hypermethylated Gastric Cancer

TypeobservationalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2024 to 2026Enrolled245ConditionsGastrectomy for Gastric Cancer, Gastrectomy, MLH1 Gene Mutation, Gastric Cancer
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Epidrugs in cancer: mechanisms, applications, and future direction.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  10. Targeting BRD4-A Promising Therapeutic Option for Glioblastoma?International journal of molecular sciences · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 6 countries.

Abdelhakim BouyahyaLaboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Genomic Center of Human Pathologies, Mohammed V University in Rabat, Rabat 10106, Morocco.ORCID 0000-0001-9317-1631
Hamza MechchateLaboratory of Biotechnology, Environment, Agri-Food, and Health (LBEAS), Faculty of Sciences, University Sidi Mohamed Ben Abdellah (USMBA), Fez 1796, Morocco.ORCID 0000-0003-4571-9089
Loubna OumeslakhtInstitute of Biological Sciences (ISSB-P), Mohammed VI Polytechnic University (UM6P), Benguerir 43150, Morocco.
Ikrame ZeoukLaboratory of Microbial Biotechnology, Faculty of Sciences and Technology, Sidi Mohamed Ben Abdellah University, Fez 1976, Morocco.
Sara AboulaghrasPhysiology and Physiopathology Team, Department of Biology, Mohammed V University in Rabat, Rabat 10106, Morocco.
Abdelaali BalahbibLaboratory of Biodiversity, Ecology, and Genome, Faculty of Sciences, Mohammed V University in Rabat, Rabat 10106, Morocco.ORCID 0000-0002-9024-4898
Gokhan ZenginPhysiology and Biochemistry Laboratory, Department of Biology, Selcuk University, Campus, Konya 42130, Turkey.ORCID 0000-0001-6548-7823
Mohammad Amjad KamalKing Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-0088-0565
Monica GalloDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy.ORCID 0000-0001-6281-426X
Domenico MontesanoDepartment of Pharmacy, University of Naples Federico II, Via D. Montesano 49, 80131 Naples, Italy.ORCID 0000-0002-8857-2091
Nasreddine El OmariLaboratory of Histology, Embryology, and Cytogenetic, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat 10100, Morocco.ORCID 0000-0002-0308-1155
Mohammed V University · MASidi Mohamed Ben Abdellah University · MAUniversity of Naples Federico II · ITKing Abdulaziz University · SASelçuk University · TRUniversité Mohammed VI Polytechnique · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a complex disease resulting from the genetic and epigenetic disruption of normal cells. The mechanistic understanding of the pathways involved in tumor transformation has implicated a priori predominance of epigenetic perturbations and a posteriori genetic instability. In this work, we aimed to explain the mechanistic involvement of epigenetic pathways in the cancer process, as well as the abilities of natural bioactive compounds isolated from medicinal plants (flavonoids, phenolic acids, stilbenes, and ketones) to specifically target the epigenome of tumor cells. The molecular events leading to transformation, angiogenesis, and dissemination are often complex, stochastic, and take turns. On the other hand, the decisive advances in genomics, epigenomics, transcriptomics, and proteomics have allowed, in recent years, for the mechanistic decryption of the molecular pathways of the cancerization process. This could explain the possibility of specifically targeting this or that mechanism leading to cancerization. With the plasticity and flexibility of epigenetic modifications, some studies have started the pharmacological screening of natural substances against different epigenetic pathways (DNA methylation, histone acetylation, histone methylation, and chromatin remodeling) to restore the cellular memory lost during tumor transformation. These substances can inhibit DNMTs, modify chromatin remodeling, and adjust histone modifications in favor of pre-established cell identity by the differentiation program. Epidrugs are molecules that target the epigenome program and can therefore restore cell memory in cancerous diseases. Natural products isolated from medicinal plants such as flavonoids and phenolic acids have shown their ability to exhibit several actions on epigenetic modifiers, such as the inhibition of DNMT, HMT, and HAT. The mechanisms of these substances are specific and pleiotropic and can sometimes be stochastic, and their use as anticancer epidrugs is currently a remarkable avenue in the fight against human cancers.

Indexed as

Epigenesis, GeneticNeoplasmsPlants, MedicinalDNA MethylationEpigenomicsFlavonoidsHistonesHumansFlavonoidsHistonescancercancer therapyDNMTepidrugsHDACpharmacodynamic

Identifiers

PMID35327559
PMCPMC8945214
OpenAlexW4214720244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.